| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
214,290,000 |
| Market
Cap: |
36.13(M) |
| Last
Volume: |
2,552,505 |
Avg
Vol: |
2,452,798 |
| 52
Week Range: |
$0.0447 - $0.65 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alaunos Therapeutics is an oncology-focused cell therapy company developing adoptive T-cell receptor (TCR) therapies, designed to treat various solid tumor types in cancer patient. Co. is utilizing its cancer mutation hotspot TCR library and its proprietary, non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from tumor-related mutations in main oncogenic genes, including KRAS, TP53 and EGFR. Co. evaluates TCRs reactive to mutated KRAS, TP53 and EGFR from its TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,000,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,300,000 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
68,014 |
68,014 |
| Total Sell Value |
$0 |
$0 |
$9,542 |
$9,542 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Belbel Caesar J |
COO, CLO, and Secretary |
• – – |
2016-12-31 |
4 |
D |
$5.35 |
$115,918 |
D/D |
(21,667) |
190,217 |
|
- |
|
| Lafond Kevin G |
Vice Pres., Treasurer & CAO |
• – – |
2016-12-31 |
4 |
D |
$5.35 |
$49,932 |
D/D |
(9,333) |
57,967 |
|
- |
|
| Fowler Wyche |
Director |
– • – |
2016-12-31 |
4 |
D |
$5.35 |
$57,052 |
D/D |
(10,664) |
140,850 |
|
- |
|
| Weiser Michael |
Director |
– • – |
2016-12-31 |
4 |
D |
$5.35 |
$49,921 |
D/D |
(9,331) |
203,670 |
|
- |
|
| Lebel Francois |
Executive Vice President R&D |
• – – |
2016-12-31 |
4 |
D |
$5.35 |
$115,918 |
D/D |
(21,667) |
137,683 |
|
- |
|
| Cooper Laurence James Neil |
Chief Executive Officer |
• – – |
2016-12-31 |
4 |
D |
$5.35 |
$92,512 |
D/D |
(17,292) |
1,209,291 |
|
- |
|
| Cannon James Anthony |
Director |
– • – |
2016-12-31 |
4 |
D |
$5.35 |
$35,658 |
D/D |
(6,665) |
352,502 |
|
- |
|
| Brennan Murray |
Director |
– • – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17,204 |
63,672 |
|
- |
|
| Belbel Caesar J |
COO, CLO, and Secretary |
• – – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
94,350 |
211,884 |
|
- |
|
| Lafond Kevin G |
Vice Pres., Treasurer & CAO |
• – – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
39,300 |
67,300 |
|
- |
|
| Fowler Wyche |
Director |
– • – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17,204 |
151,514 |
|
- |
|
| Weiser Michael |
Director |
– • – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17,204 |
213,001 |
|
- |
|
| Lebel Francois |
Executive Vice President R&D |
• – – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
94,350 |
159,350 |
|
- |
|
| Cooper Laurence James Neil |
Chief Executive Officer |
• – – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
212,250 |
1,226,583 |
|
- |
|
| Cannon James Anthony |
Director |
– • – |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17,204 |
359,167 |
|
- |
|
| Intrexon Corp |
10% Owner |
– – • |
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17,204 |
139,513 |
|
- |
|
| Brennan Murray |
Director |
– • – |
2016-11-25 |
4 |
D |
$7.22 |
$97,347 |
D/D |
(13,483) |
46,468 |
|
- |
|
| Brennan Murray |
Director |
– • – |
2016-11-25 |
4 |
OE |
$6.49 |
$97,350 |
D/D |
15,000 |
59,951 |
|
- |
|
| Belbel Caesar J |
COO, CLO, and Secretary |
• – – |
2016-06-01 |
4 |
D |
$7.74 |
$51,603 |
D/D |
(6,667) |
117,534 |
|
- |
|
| Cooper Laurence James Neil |
Chief Executive Officer |
• – – |
2016-05-05 |
4 |
D |
$6.86 |
$800,336 |
D/D |
(116,667) |
1,014,333 |
|
- |
|
| Cannon James Anthony |
Director |
– • – |
2016-04-21 |
4 |
OE |
$5.01 |
$75,150 |
D/D |
15,000 |
341,963 |
|
- |
|
| Weiser Michael |
Director |
– • – |
2016-04-19 |
4 |
D |
$8.88 |
$95,469 |
D/D |
(10,751) |
195,797 |
|
- |
|
| Weiser Michael |
Director |
– • – |
2016-04-19 |
4 |
OE |
$5.01 |
$75,150 |
D/D |
15,000 |
206,548 |
|
- |
|
| Fowler Wyche |
Director |
– • – |
2016-04-04 |
4 |
D |
$7.92 |
$92,616 |
D/D |
(11,694) |
134,310 |
|
- |
|
| Fowler Wyche |
Director |
– • – |
2016-04-04 |
4 |
OE |
$5.01 |
$75,150 |
D/D |
15,000 |
146,004 |
|
- |
|
198 Records found
|
|
Page 6 of 8 |
|
|
